heart icon heart icon
Our Stories
Our Company
Follow Us
Explore more Johnson & Johnson sites:
Australia
Argentina
Brazil
Canada
Chile
China
Colombia
Costa Rica
Czech Republic
Ecuador
Germany
India
Japan
Mexico
New Zealand / Pacific
Paraguay
Peru
Philippines
Russia
Switzerland
German
English
French
Italian
United States
Uruguay
Venezuela
Share

Media Center

Read the Story
"We Weren't Supposed to Get Tuberculosis": Meet Two Surprising Survivors Who Could Be You
"We Weren't Supposed to Get Tuberculosis": Meet Two Surprising Survivors Who Could Be You
Meet 5 Change Agents Who Are Helping Advance Gender Balance
Janssen Announces U.S. FDA Approval of SPRAVATOTM (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief
5 Important Facts About the Safety of Talc

Latest Press Releases

Innovation
March 20, 2019
Johnson & Johnson Joins Forces with Monash University-led Partnership to Advance Novel Technology Aimed at Saving Lives of Women in Child Birth
Latest News
March 19, 2019
Johnson & Johnson to Host
Investor Conference Call on First-Quarter Results
Innovation
March 18, 2019
XARELTO® (rivaroxaban) Significantly Reduced the Risk of Overall Strokes and the Most Severe Strokes and Was Associated with Fewer Stroke-Related Deaths in the Real World Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation
Innovation
March 15, 2019
Interim Analysis Showed Treatment with OPSUMIT® (macitentan) Associated with Significant Improvement in Right Ventricular (RV) Function and Pulmonary Vascular Resistance (PVR) in Patients with Pulmonary Arterial Hypertension (PAH)
Innovation
March 12, 2019
Janssen Submits Application to U.S. FDA Seeking Approval of DARZALEX® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible
Innovation
March 11, 2019
XARELTO® (rivaroxaban) Significantly Reduced Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation in Large, Real-World Meta-Analysis of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs)
See All Press Releases

Photos, Videos, Infographics & More

See All

J&J Fast Facts

Our Company
We Work All Over the World
We Work All Over the World
We have over 134,000 employees working across more than 260 operating companies located in 60 countries around the world.
Get to know Johnson & Johnson
See All Fast Facts

Social Media

  • As part of our commitment to bettering #HealthforHumanity and sustainability, we’ve completed water risk assessment… https://t.co/Je1oRrMy8E
    JNJNews
  • RT @JNJGlobalHealth: A world without TB is at the heart of achieving #HealthForAll. How TB prevention and treatment improves care for the m…
    JNJNews
  • RT @donateaphoto: Most of us are fortunate to take clean water for granted, but there’s dire need in many parts of the world. This #WaterDa…
    JNJNews
Follow Us On Twitter

More from Johnson & Johnson

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue